France· FR:61863110
TYSABRI 150 mg, solution injectable en seringue préremplie
A medicinal product containing natalizumab, registered in France by BIOGEN NETHERLANDS (PAYS-BAS).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- NATALIZUMAB
- Manufacturer
- BIOGEN NETHERLANDS (PAYS-BAS)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009303185532 seringue(s) préremplie(s) en verre de 1 ml
- cip1334009550803812 seringue(s) préremplie(s) en verre de 1 ml ( abrogée le 14/05/2025)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Natalizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandTysabri 150 mg solution for injection in pre-filled syringeBiogen Netherlands B.V.
- NetherlandsTysabri 150 mg oplossing voor injectie in een voorgevulde spuitBiogen Netherlands B.V.
- FinlandTyrukoAbacus Medicine A/S
- CzechiaTYRUKOSandoz GmbH, Kundl
- SpainTYRUKO 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONSandoz Gmbh
- BelgiumTyruko 300 mgSandoz
- SwitzerlandTyruko 300 mg / 15 ml, Konzentrat zur Herstellung einer InfusionslösungSandoz Pharmaceuticals AG
- IcelandTyrukoSandoz GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tyruko, Tysabri
- Liechtenstein · Tyruko, Tysabri
- Norway · Tyruko, Tysabri
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a5b36176-41cc-432b-ab70-a2f191c6e516 GET /v1/drugs/a5b36176-41cc-432b-ab70-a2f191c6e516?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61863110",
"date_amm": "2021-03-26",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/06/346",
"substance": "NATALIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about natalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.